Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
~ New preclinical results presented at SABCS demonstrate LP-184 has superior anti-tumor efficacy for TNBC, as compared to current TNBC standard of care agents. ~ LP-184 has therapeutic potential not only for primary TNBCs, but also for brain metastases (mets.) stemming from primary TNBC tumors. ~ Each year in the US, there are approximately 8,000 newly diagnosed TNBC patients with an additional 21,000 relapsed TNBC patients, representing an annual market potential of up to $1.7 billion USD. ~ Expanding LP-184's development indications to include TNBC further increases the long-term, potential value of LP-184 across multiple solid tumors that have unmet or underserved patient needs.
To create an account please click on this link.
If you already have an account, please log in here.